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Prognostic significance of minimal residual disease 
detected by a simplified flow cytometric assay during 
remission induction chemotherapy in children with 
acute lymphoblastic leukemia
Purpose: Our study attempted to determine the prognostic significance 
of minimal residual disease (MRD) detected by a simplified flow 
cytometric assay during induction chemotherapy in children with 
B-cell acute lymphoblastic leukemia (B-ALL).
Methods: A total of 98 patients were newly diagnosed with precursor 
B-ALL from June 2004 to December 2008 at the Asan Medical 
Center (Seoul, Korea). Of those, 37 were eligible for flow cytometric 
MRD study analysis on day 14 of their induction treatment. The flow 
cytometric MRD assay was based on the expression intensity of CD19/
CD10/CD34 or aberrant expression of myeloid antigens by bone 
marrow nucleated cells. 
Results: Thirty-five patients (94.6%) had CD19-positive leukemic cells 
that also expressed CD10 and/or CD34, and 18 (48.6%) had leukemic 
cells with aberrant expression of myeloid antigens. Seven patients 
with ≥1% leukemic cells on day 14 had a significantly lower relapse-
free survival (RFS) compared to the 30 patients with lower levels (42.9 
% [18.7%] vs. 92.0% [5.4%], P=0.004). Stratification into 3 MRD 
groups (≥1%, 0.1-1%, and <0.1%) also showed a statistically significant 
difference in RFS (42.9% [18.7%] vs. 86.9% [8.7%] vs. 100%, P= 0.013). 
However, the MRD status had no significant influence on overall 
survival. Multivariate analysis demonstrated that the MRD level on day 
14 was an independent prognostic factor with borderline significance.
Conclusion: An MRD assay using simplified flow cytometry during 
induction chemotherapy may help to identify patients with B-ALL 
who have an excellent outcome and patients who are at higher risk for 
relapse.
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Introduction
Over the past several decades, there have been remarkable 
improvements in the outcomes of pediatric acute lymphoblastic 
leukemia (ALL) patients, with cure rates achieving greater than 
80%
1). Nevertheless, significant issues are still to be solved. Relapse 
accounts for the main cause for treatment failure in the remaining 
20% of patients. Other issues involve treatment­related morbidity 
and mortality due to over­treatment. The principle of a risk­adapted 
treatment has been at the core of childhood ALL therapy, and has 
contributed greatly to treatment outcome improvements. Besides 
conventional risk factors such as gender, age, white blood cell 
(WBC) count at diagnosis, and molecular cytogenetic aberrations, 
measurement of submicroscopic levels of residual leukemic blasts, 
minimal residual disease (MRD), has proven to be a powerful 
prognostic factor in predicting relapse, refining risk stratification 
schemes for childhood ALL
2­7). 
Currently established techniques for MRD monitoring involve 
multiparametric flow cytometry and polymerase chain reaction 
(PCR)­based methods
8). Flow cytometric assay can detect the 
leukemic blasts expressing abnormal immunophenotypes, while 
PCR techniques can be used to detect tumor­specific fusion 
transcripts or clone­specific immunoglobulin (Ig) and T­cell 
receptor (TCR) gene rearrangements. Although these methods are 
sufficiently sensitive, specific, and quantitative, its accessibility is 
limited under resource­limited settings, because they are expensive, 
time consuming, and technically demanding
9). 
More simplified methods for MRD detection during the early 
period of treatment have been reported to help identify patients at 
a high risk of relapse
10­12). The purpose of our study was to analyze 
the results of a simplified flow cytometric assay based on aberrant 
expression of myeloid antigens or expression of CD19/CD10/
CD34, and to determine the prognostic significance of MRD 
detected by flow cytometry during induction chemotherapy in 
children with ALL. 
 Materials and methods
1. Patients and treatment
From June 2004 to December 2008, 98 patients were newly 
diagnosed as having precursor B­ALL at Asan Medical Center (Seoul, 
Korea). Among the 98 patients, 37 patients whose flow cytometric 
MRD data were available on day 14 of remission induction 
therapy were enrolled in the study. Data on demographics, 
diagnostic immunophenotyping, molecular cytogenetic risk 
factors, flow cytometric MRD assay, and treatment outcomes were 
retrospectively reviewed from the pediatric hematology/oncology 
database and electronic medical records at Asan Medical Center. 
The study was approved by the Institutional Review Board of the 
Asan Medical Center.
Patients were treated based on National Cancer Institute (NCI) 
age/WBC criteria and molecular cytogenetic risk factors. Patients 
were considered to have standard risk ALL if they were ≥1 and < 
10 years old with a leukocyte count lower than 50×10
9/L without 
molecular cytogenetic risk factors at presentation. Molecular 
cytogenetic abnormalities of TEL/AML1 rearrangement and 
hyperdiploidy were considered low risk features. All other patients 
were considered as having high risk ALL. Patients who had 
cytogenetic abnormalities of t(9;22), hypodiploidy, or t(4;11) were 
designated as very high risk patients irrespective of age and WBC 
count at presentation. 
No significant differences were observed between patients who 
were included (n=37) and not included (n=61) in the present study 
for median age (P=0.314), age group (P=0.439), gender (P=1.000), 
WBC count group (P=0.272), NCI risk group (P=0.830) and 
molecular cytogenetic risk (P=0.951). The 3­year overall survival 
(OS) and relapse­free survival (RFS) of the patients included in the 
present study were 88.8%±5.3%, and 84.4%±6.5%, respectively, 
which was comparable to those of the patients not included in the 
present study with OS and RFS of 84.5%±4.8% (P=0.822) and 
90.6%±4.0%, respectively (P=0.356).
The chemotherapy protocols were based on Children’s Cancer 
Group (CCG)­1881, CCG­1882, and Children’s Oncology Group 
(COG)­AALL0331 protocols. Induction chemotherapy consisted 
of glucocorticoids, vincristine, and L­asparaginase with intrathecal 
cytarabine and methotrexate for standard risk patients. For high 
risk and very high risk patients, induction chemotherapy consisted 
of glucocorticoids, vincristine, L­asparaginase, with the additional 
of daunorubicin with intrathecal cytarabine and methotrexate. 
Morphological assessments of treatment response were performed 
on day 7, 14, and 28 with or without flow cytometric MRD assay 
at the physician’s discretion. Flow cytometric MRD assays on day 
7 and 28 were excluded from this study. The bone marrow status 
was graded as M1, M2, and M3 marrow, which were based on the 
percentages of residual blasts by morphological assessment (less 
than 5%, 5­25%, and greater than 25%, respectively). Patients 
were categorized as rapid early responder (RER, M1 marrow on 
day 7, or M2 or M3 marrow on day 7 and M1 marrow on day 
14) and slow early responder (SER, M2 or M3 marrow on day 14 
and M1 marrow on day 28) based on morphological response to 
chemotherapy. SER patients received intensified post­induction 
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previously
13).
2. Flow cytometric MRD assay
Combination of immunophenotypic markers for MRD detec­
tion was based on diagnostic immunophenotyping of leukemic 
blasts. When leukemic blasts expressed myeloid aberrant markers 
such as CD13 and/or CD33, 4­color antibody combinations 
of CD19/CD13/CD34/CD45 or CD19/CD33/CD34/CD45 
were used. For patients with blasts which expressed no aberrant 
antigen on presentation, we determined the percentage of CD19­
positive cells expressing CD10 and/or CD34 with combination 
of CD19/CD10/CD34/CD45. In the bone marrow samples of 
healthy subjects, expression of CD19 with CD10 and/or CD34 
indicates normal B­lymphoid precursors or hematogones
14). Since 
these cells are highly sensitive to glucocorticoids, bone marrow 
nucleated cells expressing CD19 with CD10 and/or CD34 on 
day 14 of induction chemotherapy can be considered as leukemic 
blasts rather than normal hematogones
12). In contrast, since it 
is more likely that expression of CD19/CD10/CD34 represents 
regenerating hematogones at the end of induction, CD19/CD10/
CD34 combination was not used to detect MRD on day 28 in our 
study. 
Four­color flow cytometric analysis was done using peridinin 
chlorophyll protein (PerCP), allophycocyanin (APC), phycoery­
thrin (PE) and fluorescein isothiocyanate (FITC) (all from Becton 
Dickinson Biosciences, San Jose, CA). Cell staining was analyzed 
with FACScan and Cell Quest software or FACScanto and 
FACS Diva software (all from Becton Dickinson, San Jose, CA). 
Mononuclear cells between 1×10
4 and 1×10
5 were analyzed in 
each sample. CD45 blast gating method was used to discriminate 
leukemic blasts from the cells of various lineages and to facilitate 
the analysis of leukemic blasts present at low frequencies
15). We 
subsequently divided the 37 patients into 3 MRD groups based on 
their MRD levels on day 14, which were the group of patients with 
MRD level of 1% or more, 0.1% to less than 1%, and less than 0.1% 
(Fig. 1). 
3. Statistical analysis
OS was defined as the time between diagnosis and death from 
any causes. RFS was defined as the time between diagnosis and 
relapse, censored at date of last time of contact or death in remission. 
Differences in the distribution of clinicobiological features by 
MRD level were compared using the χ
2 analysis or Fisher’s exact 
test. The probability of OS and RFS was estimated using the 
Kaplan–Meier method. Univariate analysis was performed using 
the log­rank test to determine associations between risk factors 
and RFS. Multivariate analysis of the predictive value of MRD 
was performed by Cox­regression analysis. P values <0.05 were 
considered statistically significant. All statistical analyses were 
performed using SPSS (Statistical Package for the Social Science, 
version 15.0, SPSS Inc, Chicago, IL).
Results
1. Patient characteristics
The clinical characteristics of the 37 patients are summarized 
in Table 1. Median patient age at diagnosis was 5.3 years (range, 
0.5 to 15.8 years) and median follow­up duration was 43 months 
(range, 17 to 70 months). Seventeen patients had low risk molecular 
cytogenetics (hyperdiploidy in 9 and TEL/AML1 rearrangement in 
8) and 3 patients had very high risk cytogenetics (hypodiploidy in 1 
and t(9;22) in 2). Based on NCI criteria and molecular cytogenetic 
risk factors, 21 patients designated as standard­risk were treated 
with 3­drug induction, while 16 patients designated as high­risk 
or very high­risk were treated with the 4­drug induction with 
additional daunorubicin.
2. Prognostic significance of MRD assay
Among the 37 eligible patients, 35 (94.6%) had CD19­positive 
leukemic cells that also expressed CD10 and/or CD34, and 18 
(48.6%) had leukemic cells with aberrant expression of myeloid 
antigens. Flow cytometric MRD assay was based on aberrant 
expression of myeloid antigens in the latter 18 patients and 
Fig. 1. Flow cytometric assay to measure minimal residual disease on day 14 of 
remission induction chemotherapy. Flow cytometric dot plots show CD19/CD10/CD34 
or CD19/CD13 expression among mononuclear cells. Flow cytometric assays from 
exemplary cases indicate MRD of ≥1% (A), ≥0.1% and <1% (B), <0.1% (C).960      KN Koh, et al. • Cytometric MRD assay in childhood ALL
expression of CD19/CD10/CD34 combination for the remaining 
19 patients. The levels of MRD were ≥1% in 7 patients (18.9%), 
≥0.1% and <1% in 18 patients (48.6%) and <0.1% in 12 patients 
(32.4%) on day 14 of induction chemotherapy. 
Table 1 shows the relation between levels of MRD on day 14 
and the clinicobiological features of the disease. The presence or 
absence of residual lymphoblasts with MRD levels of ≥ 1% on 
day 14 was not significantly related to age, gender, WBC count 
at diagnosis, leukemic involvement of CNS, NCI risk status, or 
molecular cytogenetic risk factors. Of note, none of the 8 patients 
with TEL­AML1 rearrangement at initial diagnosis had MRD 
of ≥1%, although this failed to reach statistical significance due 
to small sample size (P=0.179). In addition, fluorescence in situ 
hybridization (FISH) on day 14 showed no evidence of TEL­
AML1 rearrangement in 6 of 8 patients with TEL­AML1 
rearrangement at initial diagnosis, which was consistent with the 
result of flow cytometric MRD assay. FISH data was not available 
in the remaining 2 patients. 
When comparing 2 groups of patients with MRD of ≥1% and of 
<0.1% on day 14, 7 patients with MRD of ≥1% had a significantly 
lower RFS than the 30 patients with lower levels of MRD 
(42.9%±18.7% vs. 92.0%±5.4%, P=0.004). Stratification into 3 
MRD groups (≥1%, 0.1­1%, <0.1%) also showed a statistically 
significant difference in RFS (42.9%±18.7% vs. 86.9%±8.7% vs. 
100%, P=0.013). Of note, no patient with MRD of <0.01% on day 
14 experienced a leukemic relapse. On the other hand, MRD levels 
on day 14 appeared to have no significant influence on OS (Fig. 2). 
Analysis of a subgroup of 21 patients who were uniformly treated 
with a 3­drug induction regimen of glucocorticoids, vincristine 
and L­asparaginase showed that MRD status on day 14 had no 
significant impact on RFS (66.7%±27.2% for MRD ≥ 1% vs. 
87.2%±8.6% for MRD <1%, P=0.476). Analysis of a subgroup of 
16 patients, who were uniformly treated with 4­drug regimen of 
vincristine, glucocorticoids and L­asparaginase and daunorubicin, 
showed a lower RFS in patients with MRD of ≥1% compared 
with those with MRD of <1%. (25%±21.7% vs. 100%, P=0.004). 
Notably, all relapsed patients who were treated with 4­drug 
induction regimen had a MRD of ≥1% on day 14.   
In a univariate analysis of recognized prognostic factors of RFS, 
including age, gender, presenting leukocyte counts, CNS leukemia, 
Table 1. MRD Level according to Patients' Clinicobiological Features
 Characteristics  Total
MRD level on day 14
P value
≥ 1% < 1%
Age (yr) 
<1 
≥1 and <10 
≥10 
Sex 
M 
F 
WBC (10
9/L) 
<50 
≥50 
NCI risk group* 
Standard 
High 
CNS leukemia 
Absent 
Present 
TEL-AML1 
Absent 
Present 
Genetics
† 
Low-risk 
Standard-risk 
Very high-risk 
1
27
9
23
14
33
4
24
13
34
3
29
8
17
17
3
0
4
3
5
2
7
0
4
3
7
0
7
0
2
4
1
1
23
6
18
12
26
4
20
10
27
3
22
8
15
13
2
0.459
0.687
0.570
0.678
1.000
0.179
0.546
*NCI-standard risk includes children aged 1 to less than 10 years who have 
a WBC count of less than 50×10
9/L at diagnosis, whereas NCI-high risk 
includes all other children 
†TEL-AML1 rearrangement or hyperdiploidy was designated as low-risk 
genetic factor, t(9;22), t(4;11), or hypodiploidy as very high-risk, and all other 
abnormalities, or normal cytogenetics as standard-risk   
Abbreviations: MRD, minimal residual disease; WBC, white blood cell; NCI, 
national cancer institute; CNS, central nervous system
Fig. 2. Comparison of the probabilities of relapse-free survival according to MRD risk groups by log-
rank tests. (A) Comparison between the 2 groups of patients with MRD of ≥1%, and <1%, and (B) 
comparison between the 3 groups of patients with MRD of ≥1%, 0.1 to 1%, and <0.1%.Korean J Pediatr 2010;53(11):957-964 • DOI: 10.3345/kjp.2010.53.11.957    961
the presence of molecular cytogenetic abnormalities and MRD 
status as listed in Table 2, molecular cytogenetic abnormalities and 
MRD levels on day 14 were identified as significant risk factors. Of 
note, among 17 patients with low risk cytogenetics, only 1 relapsed 
patient was documented to have a MRD level of ≥1% on day 14. 
When MRD status on day 14, molecular cytogenetic risk factors as 
well as all other clinicobiological parameters listed in Table 2 were 
evaluated by multivariate analysis, MRD status on day 14 retained 
borderline significance (OR 5.79, 95% confidence interval, 0.86­
39.2, P=0.07).
To determine if the flow cytometric MRD assay on day 14 
provided additional information to that provided by conventional 
morphological assessment, we evaluated the concordance between 
morphological assessment and flow cytometric MRD assay (Fig. 
3). Among 32 patients with an M1 marrow on day 14, 11 patients 
had MRD of <0.1%, 17 had MRD of ≥0.1% and <1%, and 4 had 
MRD ≥1%. Four patients with MRD of ≥1% had a lower RFS with 
borderline significance than the 28 patients with MRD of <1% 
(50.0%±25.0% vs. 91.6%±5.7%, P=0.07). Among 4 patients with 
an M2 marrow on day 14, 2 patients showed discordance between 
flow cytometric MRD assay and morphological evaluation, in 
that the flow cytometric assay showed MRD of <0.1%. Of note, 
2 patients with an M2 marrow and MRD of <1% remained in 
remission after induction chemotherapy without relapse, whereas 
the other 2 patients with an M2 marrow and MRD of >1% 
experienced relapse during treatment. 
Discussion
Measurement of blast clearance during initial treatment has 
been consistently shown to be a significant prognostic indicator for 
childhood ALL therapy
8, 16). Complex and sophisticated methods 
such as PCR­based techniques or multiparametric flow cytometry 
have been developed and evaluated to detect MRD. Measurement 
of MRD levels during treatment have been adopted by several 
cooperative group studies for risk­adapted treatment of childhood 
ALL. 
Our study has demonstrated that MRD levels detected by a 
simplified flow cytometric assay on day 14 of induction chemo­
therapy had significant impact on RFS, which confirms the results 
Table 2. Univariate Analysis of the Prognostic Significance of MRD 
Level on Day 14 and Other Clinicobiological Factors in Childhood 
Precursor B-ALL
Prognostic factor  No. of patients RFS (%) P value
MRD on day14 
<1% 
≥1% 
Age (yr)
<1 
≥1 and <10 
≥10 
Sex 
M 
F 
WBC (10
9/L) 
<50 
≥50 
NCI risk group* 
Standard 
High 
CNS leukemia 
Absent 
Present 
TEL-AML1 
Absent 
Present 
Genetics
† 
Low-risk 
Standard-risk 
Very high-risk 
Induction regimen
‡ 
3-drug 
4-drug 
7
30
1
27
9
23
14
33
4
24
13
34
3
29
8
17
17
3
21
16
92.0±5.4
42.9±18.7
100.0
80.4±9.1
72.9±6.5
81.8±9.9
75.0±12.5
76.6±8.7
100.0
78.0±10.2
81.5±11.9
77.6±8.4
100.0
72.4±10.0
100.0
92.9±6.9
69.1±13.7
50.0±35.4
83.3±8.9
73.3±13.0
0.004
0.654
0.453
0.380
0.898
0.483
0.141
0.004
0.667
*NCI-standard risk includes children aged 1 to less than 10 years who have 
a WBC count of less than 50×10
9/L at diagnosis, whereas NCI-high risk 
includes all other children 
†TEL-AML1  rearrangement or hyperdiploidy was designated as low-risk 
genetic factor, t(9;22), t(4;11), or hypodiploidy as very high-risk, and all other 
abnormalities, or normal cytogenetics as standard-risk
‡Three-drug induction regimen consisted of glucocorticoids, vincristine, 
and L-asparaginase, whereas 4-drug induction regimen included additional 
daunorubicin 
Abbreviations: ALL, acute lymphoblastic leukemia; RFS, relapse-free survival; 
MRD, minimal residual disease; WBC, white blood cell; NCI, national cancer 
institute; CNS, central nervous system
Fig. 3. Comparison between the morphological assessments of bone 
marrow aspirates and the flow cytometric MRD assay on day 14 of 
remission induction chemotherapy (M1, M2, and M3 marrow indicate 
less than 5%, 5% to 25%, and more than 25% of residual blasts by 
morphological assessment, respectively).962      KN Koh, et al. • Cytometric MRD assay in childhood ALL
of previous studies
6, 7, 17). Results of Total Therapy studies (XIIIA, 
XIIIB, XIV, XVA) at St. Jude Children’s Research Center have 
shown that low levels of MRD (0.001% to <0.01%) at the end 
of remission induction therapy have prognostic significance 
in childhood ALL
6). The large­scale, collaborative prospective 
study, Associazione Italiana di Ematologia Pediatrica and Berlin­
Frankfurt­Műnster (AIEOP­BFM)­ALL 2000 study of childhood 
ALL included 3,184 children and demonstrated that quantitative 
assessment of MRD based on Ig and TCR gene rearrangements 
as PCR targets at 2 time points was highly predictive for relapse 
in childhood precursor B­ALL
7). Of note, complementary 
measurement of flow cytometric MRD on day 15 bone marrow 
has been reported to be the most powerful early predictor of relapse 
in the AIEOP­BFM­ALL 2000 trial, which is consistent with our 
observation
17). 
Multivariate analysis suggested that the MRD level on day 14 
was an independent prognostic factor with borderline significance 
(P=0.07). These results did not confirm the superiority of MRD 
levels over other risk factor probably due to the small sample size. 
Of note, only one relapsed patient with low­risk genetics had a high 
level of MRD on day 14. AIEOP­BFM­ALL 2000 trial has shown 
that PCR­based MRD assessment was superior over conventional 
risk factors such as WBC at presentation, age, early response to 
prednisone, and molecular cytogenetic risk factors in discriminating 
prognosis
7). This means that MRD levels can help further stratify 
the group of patients defined by genetic risk factors such as TEL­
AML1 rearrangement, favorable DNA index, or t(9;22) into 
different prognostic subgroups. Thus, MRD assessment during 
treatment should be incorporated into the treatment regimen 
to redefine the traditional risk stratification scheme. This may 
help better discriminate the patients who require more intensive 
treatments even when they present with low­risk features, and those 
who might be treated without allogeneic hematopoietic stem cell 
transplantation even with very high­risk cytogenetics.
Morphological assessment, albeit useful and applicable at any 
center, has proven to be subjective, of limited sensitivity and 
imprecise for the study of early response to treatment
18, 19). As shown 
in our study, 32 patients with M1 marrow on day 14 could be 
stratified into MRD risk groups based on flow cytometry. It is also 
noteworthy that 2 patients with M2 marrow had MRD of <1% 
detected by flow cytometry. Those 2 patients remain in remission 
without relapse. It is possible that in these cases residual diseases 
might be overestimated by morphological assessment, although 
such discrepancy cannot be fully interpreted with the simplified 
assay alone. These findings suggest that early treatment response 
cannot be assessed successfully by morphological assessment 
alone, and MRD detection can be employed for the stratification 
of patients into early response groups. As well, the prognostic 
value for day 19 bone marrow status defined by flow cytometry 
has been reported to be superior to that defined by morphological 
evaluation
20).
The 2 major methods that have been employed for MRD 
detection and monitoring include PCR­based methodologies 
which evaluate a leukemia­specific fusion gene or a clone­specific 
rearrangement of Ig or TCR genes, and quantitative flow cytometry 
which monitors abnormal immunophenotypic markers present on 
the cell surface of the leukemic blasts
8). However, these methods 
are expensive, laborious, complex, and require considerable medical 
resources
9, 11, 12). Thus, MRD detection is accessible only in large 
research hospitals, and usually unavailable in most treatment 
centers, especially in resource­poor settings such as developing 
countries or public health insurance setting which controls the use 
of expensive medical resources. 
Our study has suggested the usefulness of the simplified flow 
cytometric MRD assay, which does not need extensive technical 
expertise, and requires a small number of antibody reagents which 
are reasonably affordable. In the present study, CD45 blast gating 
method was used to efficiently discriminate leukemic blasts form 
cells of various lineages and to facilitate the analysis of leukemic 
blasts present at low frequencies
15). Subsequent MRD assays 
were based on either one of the following two combinations of 
immunophenotypic markers: expression of myeloid aberrant 
antigens or simultaneous expression of CD19, CD10, and CD34. 
Detection of aberrant myeloid expression is sensitive and easily 
accessible with a small number of markers, but has limited 
applicability because aberrant myeloid antigens are expressed only 
in some patients. In our study, half of the enrolled patients had 
leukemic blasts expressing aberrant myeloid antigens. However, 
actual frequency of aberrant myeloid expression might be lower 
in the original population, because patients with blasts expressing 
aberrant myeloid antigens tended to be enrolled in the study more 
frequently due to easy accessibility to MRD monitoring. CD13 
has been reported to be expressed in 10­20% of patients with 
ALL, and CD33 in 5­10% in previous studies
21). CD19/CD10/
CD34 combination was used alternatively for the patients who 
lacked expression of aberrant myeloid antigens. The rationale for 
this strategy was described by Coustan­Smith et al
12). Normal 
immature CD19­positive cells expressing CD10 and/or CD34 
usually indicate benign B­cell precursors of the regenerating 
marrow, hematogones
14). These cells have been shown to be 
consistently undetectable in bone marrow samples collected from 
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chemotherapy, because of their high sensitivity to glucocorticoids 
and other anti­leukemic drugs
12). Therefore, it is reasonable that 
any cells with this immunophenotype detected in patients with 
precursor B­ALL after 2 weeks of induction chemotherapy 
can be considered as residual leukemic cells rather than normal 
B­lymphoid precursors. Coustan­Smith et al. evaluated the 
correlation between levels of CD19­positive lymphoblasts after 
2 weeks of induction chemotherapy and residual leukemic cells 
measured by 2 established MRD assays of multiparametric flow 
cytometric detection based on the abnormal immunophenotype of 
leukemic cells at diagnosis and PCR detection of Ig and TCR gene 
rearrangements. They have reported a remarkable concordance 
of results between the simplified assays based on CD19/CD10/
CD34 expression and the more complex assays, and showed the 
applicability of the simplified flow cytometric MRD assay in the 
clinical setting. However, use of the combination of CD19/CD10/
CD34 at other time points such as end of induction chemotherapy 
or during consolidation chemotherapy cannot be feasible because 
normal B­cell progenitors in regenerating bone marrow during 
those periods will necessarily produce false­positive results. High 
incidence of hematogones reaching 50.7% was reported in samples 
from precursor B­ALL patients under complete remission
22). Thus, 
at these time points, aberrant myeloid antigen expression can be 
used for MRD detection. For the patients who lack expression of 
aberrant CD13/CD33, expression of other aberrant markers such as 
CD15, CD56, CD65, and CD66, or markers expressed at different 
stages of normal B­cell maturation can be used to detect MRD at 
various time points during treatment
16). With all of these marker 
combinations, approximately 90% of B­lineage ALL cases can be 
studied at the 1 in 10
4 level of sensitivity, although complexity of 
analysis and high costs may restrict their use in resource­limited 
setting. 
Previous studies have demonstrated that simplified MRD 
monitoring predicted treatment outcomes successfully. Coustan­
Smith et al. analyzed 84 uniformly treated children using simplified 
flow cytometric assay on day 19 of induction chemotherapy in 
the St. Jude Total Therapy study XIIIB
12). They reported that the 
10­year incidence of relapse or remission failure was significantly 
higher for patients with 0.01% or more leukemic cells on day 19
12). 
A simplified MRD PCR method with consensus primers for Ig 
and TCR gene rearrangements rather than standard PCR method 
using tailor­made reagents for each patient have been reported to 
have a significant value in discriminating between good and poor 
responders among children with ALL
10, 11, 23). Our study provides 
supportive evidence for the feasibility of a simplified MRD assay 
using minimal immunophenotypic markers. Moreover, we used 
aberrant myeloid expression to supplement the simplified method. 
These strategies of MRD monitoring are applicable to nearly all 
patients with precursor B­ALL during induction chemotherapy 
with reasonable resource requirements. 
Our study has several limitations: the sample size was small, 
and patient inclusion was not consecutive due to inconsistent data 
availability. In addition, our method is applicable only during 
induction chemotherapy. Current clinical trials usually adopt 
MRD monitoring strategy at 2 or more time points
7, 24, 25), since 
analysis of MRD at one time point is less sufficient for predicting 
treatment outcomes
4, 5). Moreover, MRD cut­off values of 0.1 to 1% 
in our study were higher than those of other clinical trials, because 
the event counts for flow cytometric analysis were relatively low. 
More flow cytometric events, usually between 1 and 5×10
5, should 
be acquired to reliably increase sensitivity for MRD detection to 
0.01 to 0.001% (i.e. at least 1 to 10 of 100,000 cells), which is the 
usual cut­off value for MRD detection in most clinical trials.
In conclusion, our study has demonstrated that MRD moni­
toring on day 14 of remission induction chemotherapy had a 
significant value in predicting relapse in childhood precursor 
B­ALL. Moreover, a simplified flow cytometric assay could 
provide additional information to that provided by morphological 
assessment. MRD quantitation has become a mandatory part of 
childhood ALL therapy. Among the issues faced in the clinical 
setting are development of simpler techniques at reasonable cost, 
and application of MRD monitoring to more extended groups of 
patients, especially those under the public health insurance system. 
We suggested the feasibility of the simplified flow cytometric assay 
which is applicable to nearly all patients and requires less medical 
resources. Further prospective trials are required because the validity 
of our findings is limited by its preliminary nature due to a small 
sample size and inconsistent enrollment. Also, serial monitoring 
of MRD by more sensitive methods such as multichannel flow 
cytometry or PCR­based technologies should be incorporated 
into cooperative group clinical trials to refine the delineation of 
treatment response groups and improve the treatment outcome. 
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